Soleno Looking to Expand Potential Therapies That Work Like DCCR

Soleno Looking to Expand Potential Therapies That Work Like DCCR

287966

Soleno Looking to Expand Potential Therapies That Work Like DCCR

Soleno Therapeutics has partnered with Vanderbilt University to develop therapies that work as ATP-dependent potassium channel activators for rare diseases, similar to the diazoxide choline controlled release (DCCR) tablets the company thinks might treat Prader-Willi syndrome (PWS). ATP-dependent potassium (or KATP) channels are proteins present in multiple body tissues. As their name suggests, these proteins regulate the movement of potassium in and out of cells, and they use ATP — adenosine triphosphate, the “energy currency” of cells — to…

You must be logged in to read/download the full post.